<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711413893</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711413893</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Influence of Abnormal Fasting Plasma Glucose on Left Ventricular Function in Older Patients With Acute Myocardial Infarction</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Shi-Wei</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711413893"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Yu-Jie</given-names>
</name>
<degrees>MD, FACC, FSCAI, FHRS</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Yu-Yang</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Da-Yi</given-names>
</name>
<degrees>MD, FACC, FESC, FHRS</degrees>
<xref ref-type="aff" rid="aff2-0003319711413893">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Yu-Jie</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0003319711413893">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nie</surname>
<given-names>Xiao-Min</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Fei</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Bin</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jia</surname>
<given-names>De-An</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fang</surname>
<given-names>Zhe</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Han</surname>
<given-names>Hong-Ya</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jian-Long</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413893">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hua</surname>
<given-names>Qi</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0003319711413893">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Hong-Wei</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-0003319711413893">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711413893"><label>1</label>12th Ward, Department of Cardiology, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China</aff>
<aff id="aff2-0003319711413893"><label>2</label>Department of Cardiology, People’s Hospital Affiliated to Peking University, Beijing, China</aff>
<aff id="aff3-0003319711413893"><label>3</label>Department of Cardiology, General Hospital of Beijing Military, Beijing, China</aff>
<aff id="aff4-0003319711413893"><label>4</label>Department of Cardiology, Beijing Xuanwu Hospital Affiliated to Capital Medical University, Beijing, China</aff>
<aff id="aff5-0003319711413893"><label>5</label>Department of Cardiology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China</aff>
<author-notes>
<corresp id="corresp1-0003319711413893">Yu-Jie Zhou, 12th Ward, Department of Cardiology, Beijing Anzhen Hospital Affiliated to Capital Medical University, An Ding Men Wai, Chao Yang District, Beijing 100029, China Email: <email>jackydang@163.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>4</issue>
<fpage>266</fpage>
<lpage>274</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We assessed whether the admission fasting plasma glucose (FPG) levels were associated with all-cause mortality and left ventricular (LV) function in older patients with acute myocardial infarction (AMI). A total of 1854 consecutive patients were categorized into 4 groups: hypoglycemia, euglycemia, mild hyperglycemia, and severe hyperglycemia. The primary outcomes were in-hospital/3-year mortality and LV function. There was a near-linear relationship between FPG and Killip class. However, no significant correlation was found between FPG levels and LV ejection fraction. Both FPG levels and Killip classes were all independent significant predictors of mortality. Compared with the euglycemia group, both the hypo- and hyperglycemia groups were associated with higher in-hospital and 3-year mortality. In older patients with AMI, the FPG values had differential influences on LV function and mortality. There was a U-shaped relationship between FPG and in-hospital/3-year mortality, and a near-linear relationship between increased admission glucose levels and higher Killip classification.</p>
</abstract>
<kwd-group>
<kwd>fasting plasma glucose</kwd>
<kwd>all-cause mortality</kwd>
<kwd>left ventricular function</kwd>
<kwd>older</kwd>
<kwd>acute myocardial infarction</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Prior studies have emphasized the association between admission randomized glucose levels and poor outcomes in patients with acute myocardial infarction (AMI).<sup>
<xref ref-type="bibr" rid="bibr1-0003319711413893">1</xref><xref ref-type="bibr" rid="bibr2-0003319711413893"/><xref ref-type="bibr" rid="bibr3-0003319711413893"/><xref ref-type="bibr" rid="bibr4-0003319711413893"/><xref ref-type="bibr" rid="bibr5-0003319711413893"/><xref ref-type="bibr" rid="bibr6-0003319711413893"/>–<xref ref-type="bibr" rid="bibr7-0003319711413893">7</xref>
</sup> It recently has been reported that fasting plasma glucose (FPG) level is superior to randomized glucose levels in predicting mortality in patients with AMI.<sup>
<xref ref-type="bibr" rid="bibr8-0003319711413893">8</xref><xref ref-type="bibr" rid="bibr9-0003319711413893"/><xref ref-type="bibr" rid="bibr10-0003319711413893"/>–<xref ref-type="bibr" rid="bibr11-0003319711413893">11</xref>
</sup> However, scant data on the relationship between FPG levels and outcomes are available. On the other hand, heart failure has been shown to promote insulin resistance and glucose intolerance,<sup>
<xref ref-type="bibr" rid="bibr12-0003319711413893">12</xref>,<xref ref-type="bibr" rid="bibr13-0003319711413893">13</xref>
</sup> raising the possibility that the association between stress hyperglycemia and adverse outcome is partly mediated through the acute reduction in left ventricular (LV) systolic performance. However, the relationship between LV dysfunction and the degree of stress hyperglycemia is not well understood.<sup>
<xref ref-type="bibr" rid="bibr14-0003319711413893">14</xref><xref ref-type="bibr" rid="bibr15-0003319711413893"/><xref ref-type="bibr" rid="bibr16-0003319711413893"/><xref ref-type="bibr" rid="bibr17-0003319711413893"/>–<xref ref-type="bibr" rid="bibr18-0003319711413893">18</xref>
</sup> Meanwhile, despite the fact that the elderly individuals represent a growing majority of AMI patients, few data are available concerning this patient population. Therefore, we assessed whether admission FPG levels were associated with all-cause mortality and LV function in older patients with AMI by analyzing data from the Beijing Elderly Acute Myocardial Infarction Study (BEAMIS).</p>
<sec id="section1-0003319711413893">
<title>Methods</title>
<sec id="section2-0003319711413893">
<title>BEAMIS Study and Patients Population</title>
<p>Beijing Elderly Acute Myocardial Infarction Study is an observational study conducted at 5 medical centers. Detailed clinical data were abstracted from medical records by trained medical record reviewers. From April 2004 to October 2006, 2016 consecutive older (age ≥65 years) patients presenting with AMI were screened. All patients underwent coronary angiography. Patients with unstable angina pectoris (myocardial biomarker levels ≤2 times the corresponding normal upper limits) were excluded. To enhance homogeneity and ensure examination of a representative cohort in the context of contemporary treatment modalities, 22 (1.1%) patients who underwent percutaneous transluminal coronary angioplasty without stent implantation and 135 (6.7%) patients who underwent bare-metal stent implantation were excluded. Five (0.2%) patients with a terminal illness were excluded. A total of 1854 patients therefore constituted the study group, and the FPG level was measured in all participants. Blood samples for FPG level determination were obtained after an overnight fast of at least 8 hours, within 24 hours of admission. Plasma glucose was enzymatically determined (glucose oxidase method). Echocardiography was performed during the hospital stay after a median of 3 days from admission (interquartile range 1-7 days). Analysis of left ventricular ejection fraction (LVEF) was carried out by echocardiography. Patients were divided into 3 groups according to their treatments: medical therapy group (39.5%), percutaneous coronary intervention (PCI) group (47.5%), and coronary artery bypass graft (CABG) group (13.0%). The medical therapy group included patients receiving conservative therapy. For the PCI and CABG groups, medications (such as aspirin, clopidogrel, β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, nitrates, antidiabetic agents, and statins, among others) were given according to American College of Cardiology/American Heart Association (ACC/AHA) guidelines in addition to revascularization. A total of 104 (5.6%) patients were treated by thrombolysis and in most of them (83 of 104) urokinase was used. The study protocol was reviewed and approved by the Ethics Committee of each participating institution.</p>
</sec>
<sec id="section3-0003319711413893">
<title>Study Definitions</title>
<p>Acute myocardial infarction was defined as a combination of 2 of the 3 following characteristics: chest pain consistent with ongoing myocardial ischemia persisting &gt;30 minutes, ischemic electrocardiographic changes, and peak myocardial biomarker (including creatine kinase MB [CK-MB] and Cardiac troponin I / Cardiac troponin T [cTnI/cTnT]) levels &gt;2 times the corresponding normal upper limits.<sup>
<xref ref-type="bibr" rid="bibr19-0003319711413893">19</xref>
</sup> Patients were classified as having recognized diabetes mellitus (DM) if their medical records contained documentation of a previous history of DM, were diagnosed with DM on admission, or were on an antidiabetic agent at the time of admission. Left ventricular function was assessed by echocardiographic measurements (LV end-diastolic diameter, LV end-systolic diameter, and LVEF), and Killip classification was done as follows: (1) individuals with no clinical signs of heart failure were assigned to Killip class I; (2) individuals with rales or crackles in the lungs, an S<sub>3</sub> gallop, and elevated jugular venous pressure were assigned to Killip class II; (3) individuals with frank acute pulmonary edema were assigned to Killip class III; (4) and Killip class IV included individuals in cardiogenic shock or hypotension (measured as systolic blood pressure lower than 90 mm Hg), and evidence of peripheral vasoconstriction (oliguria, cyanosis, or sweating).<sup>
<xref ref-type="bibr" rid="bibr20-0003319711413893">20</xref>
</sup>
</p>
</sec>
<sec id="section4-0003319711413893">
<title>Outcomes</title>
<p>The primary outcomes were in-hospital and 3-year mortality and LV function during admission.</p>
</sec>
<sec id="section5-0003319711413893">
<title>Statistical Analysis</title>
<p>All case record form data were entered into 2 Epidata 3.1 databases (the Epidata Association, Denmark) by different people. Analyses were conducted with the SPSS 16.0 software package (SPSS Inc, Chicago, Illinois). Baseline demographic and clinical characteristics were compared by use of Pearson χ<sup>2</sup> test for categorical variables and the analysis of variance (ANOVA) test for continuous variables. The unadjusted association between groups of admission FPG level and in-hospital and 3-year mortality was tested with Pearson χ<sup>2</sup> test. Cox proportional models were used to assess whether the association between admission FPG level and in-hospital and 3-year mortality was independent of other characteristics. Variables clinically considered or previously demonstrated to be of prognostic importance and those identified in bivariate analyses as predictors of in-hospital and 3-year mortality were entered into the models.<sup>
<xref ref-type="bibr" rid="bibr21-0003319711413893">21</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section6-0003319711413893">
<title>Results</title>
<sec id="section7-0003319711413893">
<title>Baseline Characteristics and Distribution of Admission FPG Levels</title>
<p>There were 1854 older patients who presented with AMI in this study: men accounted for 62.6% of the population, while ST-segment elevation AMI accounted for 79.5% of presentations. Baseline characteristics, medical history, and diagnosis at presentation of the patient cohort according to FPG level are given in <xref ref-type="table" rid="table1-0003319711413893">Table 1</xref>
. In the overall cohort, mean age was 72.5 ± 5.5 years (range, 65-92 years). Only a minority of patients (24.6%) had a history of recognized DM. There were 46.6% and 26.4% patients assigned to Killip classes I and II, respectively, with the rest meeting criteria for Killip class III or IV.</p>
<table-wrap id="table1-0003319711413893" position="float">
<label>Table 1.</label>
<caption>
<p>Baseline Characteristics According to FPG Level</p>
</caption>
<graphic alternate-form-of="table1-0003319711413893" xlink:href="10.1177_0003319711413893-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>
</th>
<th align="center" colspan="5">Admission FPG (mmol/L)</th>
</tr>
<tr>
<th>Characteristics</th>
<th>Overall (N = 1854)</th>
<th>≤5 (N = 443)</th>
<th>5-7 (N = 812)</th>
<th>7-9 (N = 308)</th>
<th>≥9.1 (N = 291)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>72.5 ± 5.5</td>
<td>72.9 ± 5.4</td>
<td>72.5 ± 5.7</td>
<td>72.3 ± 5.0</td>
<td>72.1 ± 5.5</td>
<td>.649</td>
</tr>
<tr>
<td>Male (%)</td>
<td>62.6</td>
<td>72.1</td>
<td>63.7</td>
<td>50.5</td>
<td>57.6</td>
<td>.006</td>
</tr>
<tr>
<td>DM (%)</td>
<td>24.6</td>
<td>11.4</td>
<td>13.3</td>
<td>39.2</td>
<td>60.9</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>57.0</td>
<td>50.7</td>
<td>54.7</td>
<td>64.6</td>
<td>64.8</td>
<td>.062</td>
</tr>
<tr>
<td>Prior MI (%)</td>
<td>10.6</td>
<td>9.7</td>
<td>10.0</td>
<td>12.8</td>
<td>11.5</td>
<td>.860</td>
</tr>
<tr>
<td>Prior stroke (%)</td>
<td>14.1</td>
<td>15.1</td>
<td>14.6</td>
<td>13.5</td>
<td>12.0</td>
<td>.909</td>
</tr>
<tr>
<td>Hyperlipidemia (%)</td>
<td>4.9</td>
<td>5.3</td>
<td>7.5</td>
<td>1.3</td>
<td>1.4</td>
<td>.068</td>
</tr>
<tr>
<td>Current smoking (%)</td>
<td>29.1</td>
<td>34.5</td>
<td>31.4</td>
<td>22.7</td>
<td>21.4</td>
<td>.135</td>
</tr>
<tr>
<td colspan="7">Killip class (%)</td>
</tr>
<tr>
<td> I</td>
<td>46.6</td>
<td>60.6</td>
<td>45.9</td>
<td>38.1</td>
<td>36.7</td>
<td rowspan="4">.011</td>
</tr>
<tr>
<td> II</td>
<td>26.4</td>
<td>22.6</td>
<td>27.8</td>
<td>27.8</td>
<td>26.7</td>
</tr>
<tr>
<td> III</td>
<td>18.0</td>
<td>9.5</td>
<td>17.6</td>
<td>23.7</td>
<td>25.6</td>
</tr>
<tr>
<td> IV</td>
<td>9.0</td>
<td>7.3</td>
<td>8.6</td>
<td>10.3</td>
<td>11.1</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>25.4 ± 3.1</td>
<td>25.0 ± 3.8</td>
<td>25.3 ± 2.8</td>
<td>27.4 ± 3.1</td>
<td>24.0 ± 2.7</td>
<td>.201</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>79.8 ± 31.4</td>
<td>78.8 ± 12.0</td>
<td>81.4 ± 23.7</td>
<td>75.6 ± 18.8</td>
<td>80.2 ± 28.5</td>
<td>.230</td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>143.9 ± 33.1</td>
<td>142.2 ± 22.6</td>
<td>144.4 ± 25.8</td>
<td>147.9 ± 29.7</td>
<td>145.8 ± 48.3</td>
<td>.783</td>
</tr>
<tr>
<td>DBP (mm Hg)</td>
<td>89.2 ± 25.5</td>
<td>83.1 ± 10.2</td>
<td>88.6 ± 7.9</td>
<td>90.3 ± 21.2</td>
<td>90.5 ± 23.9</td>
<td>.334</td>
</tr>
<tr>
<td colspan="7">Initial laboratory tests</td>
</tr>
<tr>
<td> CK-MB (U/L)</td>
<td>248.2 ± 42.7</td>
<td>229.3 ± 17.8</td>
<td>259.5 ± 24.9</td>
<td>241.3 ± 14.4</td>
<td>279.4 ± 13.6</td>
<td>.098</td>
</tr>
<tr>
<td> TnI (ng/mL)</td>
<td>46.2 ± 20.9</td>
<td>39.6 ± 7.3</td>
<td>43.8 ± 9.6</td>
<td>41.5 ± 7.0</td>
<td>55.6 ± 6.7</td>
<td>.121</td>
</tr>
<tr>
<td> Creatinine (μmol/L)</td>
<td>98.9 ± 59.1</td>
<td>106.0 ± 78.4</td>
<td>96.7 ± 54.1</td>
<td>90.0 ± 33.3</td>
<td>103.5 ± 58.4</td>
<td>.165</td>
</tr>
<tr>
<td> FPG (mmol/L)</td>
<td>7.0 ± 3.2</td>
<td>4.5 ± 0.5</td>
<td>5.9 ± 0.6</td>
<td>7.9 ± 0.6</td>
<td>13.0 ± 3.6</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> LDL-C (mmol/L)</td>
<td>2.7 ± 0.9</td>
<td>2.7 ± 1.0</td>
<td>2.6 ± 0.8</td>
<td>2.7 ± 0.9</td>
<td>3.1 ± 1.0</td>
<td>.001</td>
</tr>
<tr>
<td> K<sup>+</sup> (mmol/L)</td>
<td>3.8 ± 0.8</td>
<td>3.7 ± 0.8</td>
<td>3.9 ± 0.6</td>
<td>3.7 ± 0.7</td>
<td>3.7 ± 1.1</td>
<td>.266</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>52.8 ± 11.5</td>
<td>53.5 ± 11.6</td>
<td>52.9 ± 11.5</td>
<td>52.0 ± 11.3</td>
<td>52.4 ± 11.7</td>
<td>.837</td>
</tr>
<tr>
<td>STEMI (%)</td>
<td>79.5</td>
<td>77.9</td>
<td>80.9</td>
<td>77.3</td>
<td>80.4</td>
<td rowspan="2">.837</td>
</tr>
<tr>
<td>NSTEMI (%)</td>
<td>20.5</td>
<td>22.1</td>
<td>19.1</td>
<td>22.7</td>
<td>19.6</td>
</tr>
<tr>
<td colspan="7">Treatments</td>
</tr>
<tr>
<td> Medical (%)</td>
<td>39.5</td>
<td>35.0</td>
<td>39.1</td>
<td>36.1</td>
<td>51.1</td>
<td rowspan="3">.241</td>
</tr>
<tr>
<td> PCI (%)</td>
<td>47.5</td>
<td>50.7</td>
<td>49.2</td>
<td>49.5</td>
<td>35.9</td>
</tr>
<tr>
<td> CABG (%)</td>
<td>13.0</td>
<td>14.3</td>
<td>11.7</td>
<td>14.4</td>
<td>13.0</td>
</tr>
<tr>
<td colspan="7">In-hospital medications</td>
</tr>
<tr>
<td> Aspirin (%)</td>
<td>96.7</td>
<td>97.1</td>
<td>97.3</td>
<td>95.9</td>
<td>95.7</td>
<td>.837</td>
</tr>
<tr>
<td> Clopidogrel (%)</td>
<td>81.8</td>
<td>83.3</td>
<td>84.6</td>
<td>75.3</td>
<td>78.3</td>
<td>.161</td>
</tr>
<tr>
<td> LMWH (%)</td>
<td>88.0</td>
<td>87.7</td>
<td>88.6</td>
<td>89.7</td>
<td>84.8</td>
<td>.740</td>
</tr>
<tr>
<td> β-Blocker (%)</td>
<td>91.4</td>
<td>88.5</td>
<td>93.7</td>
<td>91.8</td>
<td>89.1</td>
<td>.280</td>
</tr>
<tr>
<td> CCB (%)</td>
<td>18.8</td>
<td>17.3</td>
<td>19.3</td>
<td>18.6</td>
<td>19.8</td>
<td>.957</td>
</tr>
<tr>
<td> ACEI (%)</td>
<td>76.7</td>
<td>70.5</td>
<td>80.0</td>
<td>74.2</td>
<td>79.3</td>
<td>.156</td>
</tr>
<tr>
<td> ARB (%)</td>
<td>15.3</td>
<td>12.2</td>
<td>16.6</td>
<td>17.5</td>
<td>14.1</td>
<td>.613</td>
</tr>
<tr>
<td> Nitrate (%)</td>
<td>0.863</td>
<td>0.906</td>
<td>0.862</td>
<td>0.845</td>
<td>0.858</td>
<td>.190</td>
</tr>
<tr>
<td> Anti-DM (%)</td>
<td>25.1</td>
<td>15.1</td>
<td>18.9</td>
<td>35.1</td>
<td>46.7</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Insulin (%)</td>
<td>2.4</td>
<td>0.9</td>
<td>1.0</td>
<td>4.2</td>
<td>6.9</td>
<td>.012</td>
</tr>
<tr>
<td> Statin (%)</td>
<td>95.9</td>
<td>92.8</td>
<td>97.3</td>
<td>98.7</td>
<td>95.7</td>
<td>.126</td>
</tr>
<tr>
<td> Thrombolytics (%)</td>
<td>5.6</td>
<td>5.0</td>
<td>5.4</td>
<td>6.2</td>
<td>7.6</td>
<td>.205</td>
</tr>
<tr>
<td colspan="7">Mortality (%)</td>
</tr>
<tr>
<td> In-hospital</td>
<td>10.3</td>
<td>10.0</td>
<td>6.6</td>
<td>11.3</td>
<td>19.6</td>
<td>.006</td>
</tr>
<tr>
<td> 3 years</td>
<td>24.5</td>
<td>23.7</td>
<td>15.8</td>
<td>30.5</td>
<td>44.0</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711413893">
<p>Abbreviations: MI, myocardial infarction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; LMWH, low-molecular-weight heparin; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Anti-DM, antidiabetic agents; FGP, fasting blood glucose; CABG, coronary artery bypass graft; CK-MB, creatine kinase MB; PCI, percutaneous coronary intervention.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The median admission FPG level was 6.0 mmol/L (range: 2.5-26.8 mmol/L), with a mean value of 7.0 ± 3.2 mmol/L. Distribution of admission FPG levels in the patient sample is shown in <xref ref-type="fig" rid="fig1-0003319711413893">Figure 1</xref>
. A large proportion of patients (84.3%) had admission FPG values between 4.1 and 10.0 mmol/L (4.1 mmol/L ≤ FPG ≤ 6 mmol/L, 47.5%; 6.1 mmol/L ≤ FPG ≤ 8 mmol/L, 26.7%; and 8.1 mmol/L ≤ FPG ≤ 10 mmol/L, 9.2%). According to admission FPG level and clinical indication, patients were categorized into 4 groups: hypoglycemia group (n = 443, 23.9%), FPG ≤5 mmol/L; euglycemia group (n = 812, 43.8%), 5.1 mmol/L ≤ FPG ≤ 7 mmol/L (5-7 mmol/L); mild hyperglycemia group (n = 308, 16.6%), 7.1 mmol/L ≤ FPG ≤ 9 mmol/L (7-9 mmol/L); and severe hyperglycemia group (n = 291, 15.7%), FPG ≥9.1 mmol/L. Groups with higher FPG levels included greater proportions of women, patients in higher Killip classes, and patients with a history of documented DM.</p>
<fig id="fig1-0003319711413893" position="float">
<label>Figure 1.</label>
<caption>
<p>Distribution of admission fasting plasma glucose (FPG) levels.</p>
</caption>
<graphic xlink:href="10.1177_0003319711413893-fig1.tif"/>
</fig>
<p>There were no significant differences among the 4 FPG level groups in other characteristics or in patients' treatment except for frequency of use of antidiabetic agents (for FPG ≤5 mmol/L, 15.1%; FPG 5-7 mmol/L, 18.9%; FPG 7-9 mmol/L, 35.1%; and FPG ≥9.1 mmol/L, 46.7%; <italic>P</italic> &lt; .001). To further clarify the reasons for the difference, we performed a stratified analysis. All patients were classified into 2 groups according to whether they had recognized DM before admission or not. As shown in <xref ref-type="table" rid="table2-0003319711413893">Table 2</xref>
, there was no significant difference regarding their treatment based on FPG levels in patients either with or without recognized DM. Accordingly, there was no significant bias regarding their treatment based on their FPG levels, while the difference in the administration rate of antidiabetic agents may be related to the prevalence of recognized DM in each group (FPG ≤5 mmol/L, 11.4%; FPG 5-7 mmol/L, 13.3%; FPG 7-9 mmol/L, 39.2%; FPG &gt;9 mmol/L, 60.9%; <italic>P</italic> &lt; .001).</p>
<table-wrap id="table2-0003319711413893" position="float">
<label>Table 2.</label>
<caption>
<p>Stratified Analysis According to Presence/Absence of Recognized DM</p>
</caption>
<graphic alternate-form-of="table2-0003319711413893" xlink:href="10.1177_0003319711413893-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="5">Recognized DM (N = 456)</th>
<th colspan="5">Unrecognized DM (N = 1398)</th>
</tr>
<tr>
<th>FPG Levels (mmol/L)</th>
<th align="center">≤5 (N = 50)</th>
<th align="center">5-7 (N = 108)</th>
<th align="center">7-9 (N = 121)</th>
<th align="center">&gt;9 (N = 177)</th>
<th align="center">
<italic>P</italic> Value</th>
<th align="center">≤5 (N = 393)</th>
<th align="center">5-7 (N = 704)</th>
<th align="center">7-9 (N = 187)</th>
<th align="center">&gt;9 (N = 114)</th>
<th align="center">
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="11">Treatments groups</td>
</tr>
<tr>
<td> Medical (%)</td>
<td>43.8</td>
<td>41.2</td>
<td>36.8</td>
<td>53.6</td>
<td rowspan="3">.726</td>
<td>33.9</td>
<td>38.7</td>
<td>35.6</td>
<td>47.2</td>
<td rowspan="3">.688</td>
</tr>
<tr>
<td> PCI (%)</td>
<td>37.5</td>
<td>47.1</td>
<td>50.0</td>
<td>35.7</td>
<td>52.4</td>
<td>49.5</td>
<td>49.2</td>
<td>36.1</td>
</tr>
<tr>
<td> CABG (%)</td>
<td>18.8</td>
<td>11.8</td>
<td>13.2</td>
<td>10.7</td>
<td>13.7</td>
<td>11.7</td>
<td>15.3</td>
<td>16.7</td>
</tr>
<tr>
<td colspan="11">In-hospital medications</td>
</tr>
<tr>
<td> Aspirin (%)</td>
<td>100.0</td>
<td>94.1</td>
<td>94.7</td>
<td>98.2</td>
<td>.572</td>
<td>96.7</td>
<td>97.7</td>
<td>96.6</td>
<td>91.7</td>
<td>.295</td>
</tr>
<tr>
<td> Clopidogrel (%)</td>
<td>75.0</td>
<td>88.2</td>
<td>81.6</td>
<td>83.9</td>
<td>.685</td>
<td>82.8</td>
<td>83.2</td>
<td>74.6</td>
<td>75.0</td>
<td>.172</td>
</tr>
<tr>
<td> LMWH (%)</td>
<td>87.5</td>
<td>91.2</td>
<td>94.7</td>
<td>89.3</td>
<td>.780</td>
<td>87.7</td>
<td>88.2</td>
<td>86.4</td>
<td>77.8</td>
<td>.386</td>
</tr>
<tr>
<td> β-Blocker (%)</td>
<td>87.5</td>
<td>97.1</td>
<td>97.4</td>
<td>91.1</td>
<td>.357</td>
<td>88.6</td>
<td>93.2</td>
<td>88.1</td>
<td>86.1</td>
<td>.311</td>
</tr>
<tr>
<td> CCB (%)</td>
<td>12.5</td>
<td>35.3</td>
<td>15.8</td>
<td>26.8</td>
<td>.163</td>
<td>17.9</td>
<td>16.8</td>
<td>20.3</td>
<td>8.6</td>
<td>.511</td>
</tr>
<tr>
<td> ACEI (%)</td>
<td>68.8</td>
<td>82.4</td>
<td>73.7</td>
<td>85.7</td>
<td>.327</td>
<td>70.7</td>
<td>79.6</td>
<td>74.6</td>
<td>69.4</td>
<td>.230</td>
</tr>
<tr>
<td> ARB (%)</td>
<td>25.0</td>
<td>38.2</td>
<td>23.7</td>
<td>12.5</td>
<td>.056</td>
<td>10.6</td>
<td>13.2</td>
<td>13.6</td>
<td>16.7</td>
<td>.777</td>
</tr>
<tr>
<td> Nitrate (%)</td>
<td>87.5</td>
<td>88.2</td>
<td>92.1</td>
<td>74.5</td>
<td>.105</td>
<td>90.2</td>
<td>85.8</td>
<td>79.7</td>
<td>80.6</td>
<td>.201</td>
</tr>
<tr>
<td> Anti-DM (%)</td>
<td>75.0</td>
<td>67.6</td>
<td>65.8</td>
<td>67.9</td>
<td>.930</td>
<td>7.3</td>
<td>11.4</td>
<td>15.3</td>
<td>13.9</td>
<td>.370</td>
</tr>
<tr>
<td> Insulin (%)</td>
<td>8.0</td>
<td>6.5</td>
<td>9.1</td>
<td>10.7</td>
<td>.206</td>
<td>0</td>
<td>0.1</td>
<td>1.1</td>
<td>0.9</td>
<td>.081</td>
</tr>
<tr>
<td> Statin (%)</td>
<td>93.8</td>
<td>100.0</td>
<td>92.1</td>
<td>98.2</td>
<td>.232</td>
<td>92.7</td>
<td>96.8</td>
<td>88.1</td>
<td>91.7</td>
<td>.056</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0003319711413893">
<p>Abbreviations: LMWH, low-molecular-weight heparin; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Anti-DM, antidiabetic agents; FGP, fasting blood glucose; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0003319711413893">
<title>Association Between Admission FPG Level and LV Function</title>
<p>There was a near-linear relationship between FPG level and Killip class (<xref ref-type="fig" rid="fig2-0003319711413893">Figure 2A</xref>). Killip class I/II was more frequent in patients with hypoglycemia, while Killip class III/IV was more frequent in patients with hyperglycemia (Killip class I for FPG ≤5 mmol/L, 60.6%; FPG 5-7 mmol/L, 45.9%; FPG 7-9 mmol/L, 38.1%; and FPG ≥9.1 mmol/L, 36.7%; Killip class II for FPG ≤5 mmol/L, 22.6%; FPG 5-7 mmol/L, 27.8%; FPG 7-9 mmol/L, 27.8%; and FPG ≥9.1 mmol/L, 26.7%; Killip class III for FPG ≤5 mmol/L, 9.5%; FPG 5-7 mmol/L, 17.6%; FPG 7-9 mmol/L, 23.7%; and FPG ≥9.1 mmol/L, 25.6%; Killip class IV for FPG ≤5 mmol/L, 7.3%; FPG 5-7 mmol/L, 8.6%; FPG 7-9 mmol/L, 10.3%; and FPG ≥11.1 mmol/L, 26.7%; <italic>P </italic>= .011). However, no significant correlation was found between admission FPG level and LVEF, LV end-diastolic or end-systolic diameter (LVEF for FPG ≤5 mmol/L, 53.5 ± 11.6%; FPG 5-7 mmol/L, 52.9 ± 11.5%; FPG 7-9 mmol/L, 52.0 ± 11.3%; FPG ≥9.1 mmol/L, 52.4 ± 11.7%; <italic>P</italic> = .837; LV end-diastolic diameter for FPG ≤5 mmol/L, 50.8 ± 7.2 mm; FPG 5-7 mmol/L, 50.9 ± 7.5 mm; FPG 7-9 mmol/L, 50.4 ± 5.9 mm; FPG ≥9.1 mmol/L, 48.5 ± 6.0 mm; <italic>P</italic> = .073; LV end-systolic diameter for FPG ≤5 mmol/L, 36.3 ± 7.9 mm; FPG 5-7 mmol/L, 36.6 ± 8.3 mm; FPG 7-9 mmol/L, 35.9 ± 7.2 mm; FPG ≥9.1 mmol/L, 34.3 ± 6.6 mm; <italic>P</italic> = .165; <xref ref-type="fig" rid="fig2-0003319711413893">Figure 2B, C, D</xref>).</p>
<fig id="fig2-0003319711413893" position="float">
<label>Figure 2.</label>
<caption>
<p>Association between admission fasting plasma glucose (FPG) levels and left ventricular (LV) function. A, Association between admission FPG levels and Killip class (Killip class I for FPG ≤5 mmol/L, 60.6%; FPG 5-7 mmol/L, 45.9%; FPG 7-9 mmol/L, 38.1%; and FPG ≥9.1 mmol/L, 36.7%; Killip class II for FPG ≤5 mmol/L, 22.6%; FPG 5-7 mmol/L, 27.8%; FPG 7-9 mmol/L, 27.8%; and FPG ≥9.1 mmol/L, 26.7%; Killip class III for FPG ≤5 mmol/L, 9.5%; FPG 5-7 mmol/L, 17.6%; FPG 7-9 mmol/L, 23.7%; and FPG ≥9.1 mmol/L, 25.6%; Killip class IV for FPG ≤5 mmol/L, 7.3%; FPG 5-7 mmol/L, 8.6%; FPG 7-9 mmol/L, 10.3%; and FPG ≥11.1 mmol/L, 26.7%; <italic>P</italic> = .011). B, Association between admission FPG levels and left ventricular ejection fraction (LVEF for FPG ≤5 mmol/L, 53.5% ± 11.6%; FPG 5-7 mmol/L, 52.9% ± 11.5%; FPG 7-9 mmol/L, 52.0% ± 11.3%; FPG ≥9.1 mmol/L, 52.4% ± 11.7%; <italic>P</italic> = .837). C, Association between admission FPG levels and LV end-diastolic diameter (LV end-diastolic diameter for FPG ≤5 mmol/L, 50.8 ± 7.2 mm; FPG 5-7 mmol/L, 50.9 ± 7.5 mm; FPG 7-9 mmol/L, 50.4 ± 5.9 mm; FPG ≥9.1 mmol/L, 48.5 ± 6.0 mm; <italic>P</italic> = .073). D, Association between admission FPG levels and LV end-systolic diameter (LV end-systolic diameter for FPG ≤5 mmol/L, 36.3 ± 7.9 mm; FPG 5-7 mmol/L, 36.6 ± 8.3 mm; FPG 7-9 mmol/L, 35.9 ± 7.2 mm; FPG ≥9.1 mmol/L, 34.3 ± 6.6 mm; <italic>P</italic> = .165).</p>
</caption>
<graphic xlink:href="10.1177_0003319711413893-fig2.tif"/>
</fig>
</sec>
<sec id="section9-0003319711413893">
<title>Association Between Admission FPG level/Killip Class and Mortality</title>
<p>In the overall cohort, a total of 190 patients (10.3%) died in hospital and 454 patients (24.5%) died during the 3-year follow-up. In a multivariable Cox model adjusting for confounding factors, both admission FPG level (<italic>P </italic>= .002) and Killip classes (<italic>P </italic>&lt; .001) were independent significant predictors of in-hospital/3-year mortality. Compared with the euglycemia group, both the hypo- and hyperglycemia groups had higher in-hospital and 3-year all-cause mortality. Patients in the FPG 5 to 7 mmol/L group had the best outcome (in-hospital mortality for FPG ≤5 mmol/L, 10.0%; FPG 5-7 mmol/L, 6.6%; FPG 7-9 mmol/L, 11.3%; and FPG ≥9.1 mmol/L, 19.6%; 3-year mortality for FPG ≤5 mmol/L, 23.7%; FPG 5-7 mmol/L, 15.8%; FPG 7-9 mmol/L, 30.5%; and FPG ≥9.1 mmol/L, 44.0%). There was a striking U-shaped relationship between admission FPG level and short- and long-term all-cause mortality in older patients with AMI (<xref ref-type="fig" rid="fig3-0003319711413893">Figure 3A</xref>). In contrast to admission FPG levels, there was a linear relationship between Killip class and all-cause mortality (<xref ref-type="fig" rid="fig3-0003319711413893">Figure 3B</xref>). Compared with Killip class I, Killip class II was associated with an increase of 43.9% in in-hospital mortality (8.2% vs 5.7%; <italic>P </italic>&lt; .001) and 5.8% in 3-year mortality (23.9% vs 22.6%; <italic>P </italic>&lt; .001). Killip class III/IV was associated with a graded increase in either in-hospital (for Killip class III, 14.2%; Killip class IV, 44.8%) or 3-year mortality (for Killip class III, 30.6%; Killip class IV, 53.6%) compared with Killip class I (<italic>P </italic>&lt; .001). The mortality of patients with different FPG levels and Killip classes is shown using 3-dimensional bar charts in <xref ref-type="fig" rid="fig3-0003319711413893">Figure 3C</xref> and <xref ref-type="fig" rid="fig3-0003319711413893">D</xref>. In-hospital mortality of patients with hypoglycemia and Killip class IV was highest in the overall cohort, followed by that of patients with severe hyperglycemia and Killip class IV (60% vs 50.0%; <italic>P </italic>= .015). In contrast, 3-year mortality of patients with severe hyperglycemia and Killip class IV was highest, followed by that of patients with hypoglycemia and Killip class IV (70% vs 60.0%; <italic>P</italic> = .001).</p>
<fig id="fig3-0003319711413893" position="float">
<label>Figure 3.</label>
<caption>
<p>Association between admission fasting plasma glucose (FPG) levels/Killip class and mortality. A, U-shaped relationship between admission FPG level and mortality. B, Linear relationship between Killip class and mortality. C, In-hospital mortality of patients with hypoglycemia and Killip class IV was highest in the overall cohort, followed by that of patients with severe hyperglycemia and Killip class IV (60% vs 50.0%; <italic>P</italic> = .015). D, A 3-year mortality of patients with severe hyperglycemia and Killip class IV was highest, followed by that of patients with hypoglycemia and Killip class IV (70% vs 60.0%; <italic>P</italic> = .001).</p>
</caption>
<graphic xlink:href="10.1177_0003319711413893-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section10-0003319711413893">
<title>Discussion</title>
<sec id="section11-0003319711413893">
<title>The Relationship Between Abnormal FPG Levels and Mortality</title>
<p>Several studies have reported that acute hyperglycemia is related to a higher mortality after acute coronary syndromes.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711413893">1</xref><xref ref-type="bibr" rid="bibr2-0003319711413893"/><xref ref-type="bibr" rid="bibr3-0003319711413893"/><xref ref-type="bibr" rid="bibr4-0003319711413893"/><xref ref-type="bibr" rid="bibr5-0003319711413893"/><xref ref-type="bibr" rid="bibr6-0003319711413893"/>–<xref ref-type="bibr" rid="bibr7-0003319711413893">7</xref>
</sup> Most of the older and smaller studies (predominantly from the 1980s and 1990s) were summarized in a meta-analysis.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711413893">1</xref>
</sup> These combined results demonstrated that the relative risk of in-hospital mortality in nondiabetic patients with AMI with an admission glucose level &gt;6.1 mmol/L was 3.9, as compared with nondiabetic patients with AMI who were euglycemic.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711413893">1</xref>
</sup> Among patients with AMI with diabetes, those with an admission glucose level &gt;10.0 mmol/L had a 70% increase in the relative risk of in-hospital mortality, as compared with diabetic patients with normal admission glucose.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711413893">1</xref>
</sup> More recent studies have confirmed these findings, showing significant increases in the risk of short- and long-term mortality, as well as heart failure, in hyperglycemia patients with AMI both with and without known diabetes.<sup>
<xref ref-type="bibr" rid="bibr2-0003319711413893">2</xref>,<xref ref-type="bibr" rid="bibr3-0003319711413893">3</xref>
</sup> These findings extend to the entire range of acute coronary syndromes, including ST-segment elevation MI, non-ST segment elevation MI, and unstable angina.<sup>
<xref ref-type="bibr" rid="bibr4-0003319711413893">4</xref>
</sup>
</p>
<p>Several studies also have documented a clear relationship between elevated fasting glucose level during AMI hospitalization and increased mortality risk.<sup>
<xref ref-type="bibr" rid="bibr8-0003319711413893">8</xref><xref ref-type="bibr" rid="bibr9-0003319711413893"/><xref ref-type="bibr" rid="bibr10-0003319711413893"/>–<xref ref-type="bibr" rid="bibr11-0003319711413893">11</xref>
</sup> In contrast to a random glucose level on admission, an elevated FPG level may better reflect abnormalities in underlying glucose metabolism, and thus may be a better predictor both of short- and long-term outcomes. One of the earlier studies on this issue<sup>
<xref ref-type="bibr" rid="bibr8-0003319711413893">8</xref>
</sup> demonstrated that while both admission and fasting glucose levels predicted 30-day mortality in nondiabetic patients with AMI, fasting glucose level was the better discriminator. In a subsequent study by the same group, using a larger patient sample size and a longer follow-up period, fasting glucose level also was shown to be a strong predictor of long-term mortality (mean follow-up 24 months) and LV systolic function post-AMI. Fasting glucose also added significantly to the discriminating ability of the Global Registry of Acute Coronary Events (GRACE) risk score (a validated tool used to estimate all-cause mortality risk in patients with acute coronary syndromes).<sup>
<xref ref-type="bibr" rid="bibr9-0003319711413893">9</xref>
</sup> The present study demonstrated an independent graded association between elevated admission FPG levels and increasing in-hospital and 3-year mortality, consistent with the above studies. This higher risk of both short- and long-term mortality persisted after controlling higher burden of comorbidities (such as prior myocardial infarction and hypertension) and greater disease severity (higher Killip class, higher peak creatine kinase and creatinine levels, and lower ejection fraction) observed in patients with elevated FPG levels.</p>
<p>The prognostic significance of hypoglycemia after AMI is controversial. Svensson et al<sup>
<xref ref-type="bibr" rid="bibr22-0003319711413893">22</xref>
</sup> conducted a study in 713 diabetic patients with unstable angina or non-Q-wave myocardial infarction and found a significantly higher mortality at 2 years in participants with hypoglycemia (admission glucose level ≤3.0 mmol/L) than in those with euglycemia; however, a causal link between in-hospital hypoglycemia and clinical outcomes ascertained 2 years later was difficult to establish. Kosiborod et al<sup>
<xref ref-type="bibr" rid="bibr23-0003319711413893">23</xref>
</sup> showed that hypoglycemia (admission glucose level &lt;3.3 mmol/L) was associated with increased mortality in patients with AMI, but this risk was confined to patients who had spontaneous hypoglycemia (ie, not including iatrogenic hypoglycemia). A more recent analysis<sup>
<xref ref-type="bibr" rid="bibr24-0003319711413893">24</xref>
</sup> revealed that both admission and postadmission hyperglycemia (admission glucose level ≤3.8 mmol/L) could predict 30-day death in patients with AMI. However, only hypoglycemia on admission predicted death, and this relationship dissipated after admission. Another report from the Diabetes mellitus, Insulin Glucose infusion in Acute Myocardial Infarction 2 (DIGAMI-2) trial<sup>
<xref ref-type="bibr" rid="bibr25-0003319711413893">25</xref>
</sup> showed that hypoglycemia (admission glucose level &lt;3.0 mmol/L) during the initial hospitalization was not an independent risk factor for future morbidity or mortality in patients with type 2 diabetes and myocardial infarction. Hypoglycemic episodes were, however, more prevalent in patients at high risk for other reasons. All trials mentioned above used a much lower threshold to define hypoglycemia, and nondiabetic participants were not included in some trials. In the present study, we observed that mild to moderately low FPG levels (≤5 mmol/L) were associated with a relative increase in mortality risk. There was a U-shaped relationship between admission FPG level and short- and long-term mortality. It was notable that although patients with hypoglycemia and Killip class IV accounted for a small proportion of the cohort, in-hospital mortality of these patients was the highest. The latter result adds to the ongoing debate regarding admission plasma glucose level in patients presenting with AMI.</p>
</sec>
<sec id="section12-0003319711413893">
<title>The Relationship Between Abnormal FPG Level and LV Function</title>
<p>In patients with AMI, the acute injury to the myocardium may lead to transient or permanent heart failure. Heart failure promotes insulin resistance and glucose intolerance,<sup>
<xref ref-type="bibr" rid="bibr12-0003319711413893">12</xref>,<xref ref-type="bibr" rid="bibr13-0003319711413893">13</xref>
</sup> raising the possibility that the association between stress hyperglycemia and adverse outcome is partly mediated through the acute reduction in LV systolic performance. Although elevated plasma glucose level is a common finding in patients with AMI, the relationship between plasma glucose concentration and LV function is not well understood. O’Sullivan et al<sup>
<xref ref-type="bibr" rid="bibr14-0003319711413893">14</xref>
</sup> and Thomassen et al<sup>
<xref ref-type="bibr" rid="bibr15-0003319711413893">15</xref>
</sup> found no correlation between glucose level and LV function, whereas Oswald et al<sup>
<xref ref-type="bibr" rid="bibr16-0003319711413893">16</xref>
</sup> and Bellodi et al<sup>
<xref ref-type="bibr" rid="bibr17-0003319711413893">17</xref>
</sup> found a weak relation between plasma glucose concentration and LV function. Recently, Ishihara et al<sup>
<xref ref-type="bibr" rid="bibr18-0003319711413893">18</xref>
</sup> found lower LVEF among patients with AMI and admission glucose level &gt;10 mmol/l. These investigators suggested that impaired LVEF might explain the poor outcomes of patients with AMI and elevated admission glucose level. In the present study, we observed a graded increase of Killip classification with increasing fasting glucose concentrations, but there was no significant correlation between FPG levels and other LV function markers. Unlike LVEF or LV end-diastolic/end-systolic diameter, higher Killip class may better reflect LV function abnormalities at the early stress stage after the onset of AMI, and thus there was a stronger relationship between FPG level and Killip class.<sup>
<xref ref-type="bibr" rid="bibr20-0003319711413893">20</xref>
</sup> Another important piece of information provided by the present study is that abnormal FPG values have differential influences on LV function and mortality. On one hand, increased and decreased admission FPG levels could predict higher in-hospital and 3-year mortality: there was a U-shaped relationship between admission FPG levels and short- and long-term mortality. On the other hand, only hyperglycemia could predict a higher incidence of Killip class III/IV, and there was a near-linear relationship between increased admission glucose level and higher Killip classification. The mechanisms behind this phenomenon are unclear. The current study suggests that although hypo-/hyperglycemia increased the risk of death, the contribution ratio of LV dysfunction in the pathophysiology process is different.</p>
<p>The exact mechanisms behind the association of hyper-/hypoglycemia and higher mortality have not been definitively established. However, prior physiological studies show that higher glucose levels in patients with AMI are associated with higher free fatty acid concentrations (which may induce cardiac arrhythmias), insulin resistance, and impaired myocardial glucose use, thus increasing the consumption of oxygen and potentially worsening ischemia.<sup>
<xref ref-type="bibr" rid="bibr26-0003319711413893">26</xref>
</sup> Hyperglycemia also has been associated with microvascular dysfunction,<sup>
<xref ref-type="bibr" rid="bibr27-0003319711413893">27</xref>
</sup> a prothrombotic state,<sup>
<xref ref-type="bibr" rid="bibr28-0003319711413893">28</xref>
</sup> vascular inflammation,<sup>
<xref ref-type="bibr" rid="bibr29-0003319711413893">29</xref>
</sup> endothelial dysfunction,<sup>
<xref ref-type="bibr" rid="bibr30-0003319711413893">30</xref>
</sup> and generation of reactive oxygen species.<sup>
<xref ref-type="bibr" rid="bibr31-0003319711413893">31</xref>
</sup> All of these mechanisms may potentiate tissue injury in the setting of AMI. Hypoglycemia and rapid changes in blood glucose level have been shown to increase the levels of counterregulatory hormones such as epinephrine and norepinephrine, which may induce vasoconstriction, platelet aggregation, and thereby ischemia.<sup>
<xref ref-type="bibr" rid="bibr32-0003319711413893">32</xref>
</sup> Furthermore, in the presence of hypokalemia and raised serum catecholamine levels, which often simultaneously present during hypoglycemia, cardiac repolarization could be prolonged enough to induce cardiac arrythmias.<sup>
<xref ref-type="bibr" rid="bibr33-0003319711413893">33</xref>
</sup> In our study, there were no significant group differences in the potassium levels.</p>
<p>Prior randomized clinical trials of glucose control in AMI have been limited primarily to patients with recognized diabetes, and their results have been inconsistent.<sup>
<xref ref-type="bibr" rid="bibr34-0003319711413893">34</xref><xref ref-type="bibr" rid="bibr35-0003319711413893"/><xref ref-type="bibr" rid="bibr36-0003319711413893"/><xref ref-type="bibr" rid="bibr37-0003319711413893"/>–<xref ref-type="bibr" rid="bibr38-0003319711413893">38</xref>
</sup> The DIGAMI study<sup>
<xref ref-type="bibr" rid="bibr34-0003319711413893">34</xref>
</sup> has been to date the only randomized trial of glucose control in AMI which achieved a significantly lower glucose level in the intervention arm compared with the control arm; it also happens to be the only randomized trial to have demonstrated a survival benefit associated with better glucose control. In the DIGAMI-2 trial,<sup>
<xref ref-type="bibr" rid="bibr35-0003319711413893">35</xref>
</sup> there was no difference in outcomes among the 1253 randomized patients with AMI (intensive treatment vs routine metabolic management). Furthermore, none of the most recently published trials (including BARI 2D,<sup>
<xref ref-type="bibr" rid="bibr36-0003319711413893">36</xref>
</sup> ADVANCE,<sup>
<xref ref-type="bibr" rid="bibr37-0003319711413893">37</xref>
</sup> and ACCORD<sup>
<xref ref-type="bibr" rid="bibr38-0003319711413893">38</xref>
</sup>) that compared different glycemic-control targets showed a significant reduction in cardiovascular events. Thus, it remains to be established whether patients would benefit from adjusting their admission glucose level after arrival, which needs to be further investigated in prospective randomized clinical trials.</p>
</sec>
</sec>
<sec id="section13-0003319711413893">
<title>Conclusions</title>
<p>In older patients with AMI, abnormal FPG values had differential influences on LV function and mortality. Not only increased but also decreased admission FPG levels predicted in-hospital and 3-year mortality with a U-shaped relationship between admission FPG levels and short- or long-term mortality, while there was a near-linear relationship between increased admission glucose levels and higher Killip classification.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors sincerely thank Roberto Patarca, MD, for revising the manuscript.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711413893">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="other" id="fn2-0003319711413893">
<p>The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license (or nonexclusive for government employees) on a worldwide basis to the Publishing Group and its Licensees to permit this article (if accepted) to be published to exploit all subsidiary rights, as set out in our license.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0003319711413893">
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Beijing Elderly Acute Myocardial Infarction Study (BEAMIS) was supported by a grant from the Beijing Municipal Science &amp; Technology Commission (No. Z0005190042811). The sponsor had no involvement in the collection, analysis or interpretation of data; in the writing of the submitted manuscript; or in the decision to submit the manuscript for publication.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711413893">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capes</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Malmberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gerstein</surname>
<given-names>HC</given-names>
</name>
</person-group>. <article-title>Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview</article-title>. <source>Lancet</source>. <year>2000</year>;<volume>355</volume>(<issue>9206</issue>):<fpage>773</fpage>–<lpage>778</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711413893">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahab</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Cowden</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>NJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?</article-title> <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>40</volume>(<issue>10</issue>):<fpage>1748</fpage>–<lpage>1754</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711413893">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stranders</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Diamant</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Gelder</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group>. <article-title>Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus</article-title>. <source>Arch Intern Med</source>. <year>2004</year>;<volume>164</volume>(<issue>9</issue>):<fpage>982</fpage>–<lpage>988</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711413893">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Deaner</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes</article-title>. <source>Heart</source>. <year>2003</year>;<volume>89</volume>(<issue>5</issue>):<fpage>512</fpage>–<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711413893">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosiborod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rathore</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</name>
<etal/>
</person-group>. <article-title>Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>111</volume>(<issue>23</issue>):<fpage>3078</fpage>–<lpage>3086</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711413893">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwakura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ikushima</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>41</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711413893">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishihara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of blood glucose values on admission for acute myocardial infarction in patients with versus without diabetes mellitus</article-title>. <source>Am J Cardiol</source>. <year>2009</year>;<volume>104</volume>(<issue>6</issue>):<fpage>769</fpage>–<lpage>774</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711413893">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suleiman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hammerman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Boulos</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>111</volume>(<issue>6</issue>):<fpage>754</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711413893">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aronson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hammerman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kapeliovich</surname>
<given-names>MR</given-names>
</name>
<etal/>
</person-group>. <article-title>Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function</article-title>. <source>Diabetes Care</source>. <year>2007</year>;<volume>30</volume>(<issue>4</issue>):<fpage>960</fpage>–<lpage>966</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711413893">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Assali</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Zahalka</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Impaired fasting glucose and outcomes of ST-elevation acute coronary syndrome treated with primary percutaneous intervention among patients without previously known diabetes mellitus</article-title>. <source>Am Heart J</source>. <year>2008</year>;<volume>155</volume>(<issue>2</issue>):<fpage>284</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711413893">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vergès</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zeller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dentan</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of fasting glycemia on short term prognosis after acute myocardial infarction</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>(<issue>6</issue>):<fpage>2136</fpage>–<lpage>2140</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711413893">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witteles</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Jamali</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Reaven</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>MB</given-names>
</name>
</person-group>. <article-title>Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link</article-title>. <source>J Am Coll Cardiol</source>. <year>2004</year>;<volume>44</volume>(<issue>1</issue>):<fpage>78</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711413893">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suskin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>McKelvie</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure</article-title>. <source>Eur Heart J</source>. <year>2000</year>;<volume>21</volume>(<issue>16</issue>):<fpage>1368</fpage>–<lpage>1375</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711413893">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Sullivan</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Conroy</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hickey</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mulcahy</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>In-hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction</article-title>. <source>Diabetes Care</source>. <year>1991</year>;<volume>14</volume>(<issue>8</issue>):<fpage>758</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711413893">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomassen</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Falstie-Jensen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Thygesen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Henningsen</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Altered plasma concentrations of glutamate, alanine and citrate in the early phase of acute myocardial infarction in man</article-title>. <source>Eur Heart J</source>. <year>1986</year>;<volume>7</volume>(<issue>9</issue>):<fpage>773</fpage>–<lpage>778</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711413893">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oswald</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Betteridge</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Yudkin</surname>
<given-names>JS</given-names>
</name>
</person-group>. <article-title>Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction</article-title>. <source>Br Med J (Clin Res Ed)</source>. <year>1986</year>;<volume>293</volume>(<issue>6552</issue>):<fpage>917</fpage>–<lpage>922</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711413893">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellodi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Manicardi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Malavasi</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus</article-title>. <source>Am J Cardiol</source>. <year>1989</year>;<volume>64</volume>(<issue>14</issue>):<fpage>885</fpage>–<lpage>888</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711413893">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishihara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kawagoe</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction</article-title>. <source>Am Heart J</source>. <year>2003</year>;<volume>146</volume>(<issue>4</issue>):<fpage>674</fpage>–<lpage>678</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711413893">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thygesen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Alpert</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>White</surname>
<given-names>HD</given-names>
</name>
</person-group>
<collab collab-type="author">Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction</collab>. <article-title>Universal definition of myocardial infarction</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>20</issue>):<fpage>2525</fpage>–<lpage>2538</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711413893">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parakh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Thombs</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Fauerbach</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Ziegelstein</surname>
<given-names>RC</given-names>
</name>
</person-group>. <article-title>Long-term significance of Killip class and left ventricular systolic dysfunction</article-title>. <source>Am J Med</source>. <year>2008</year>;<volume>121</volume>(<issue>11</issue>):<fpage>1015</fpage>–<lpage>1018</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711413893">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krumholz</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Murillo</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Thrombolytic therapy for eligible elderly patients with acute myocardial infarction</article-title>. <source>JAMA</source>. <year>1997</year>;<volume>277</volume>(<issue>21</issue>):<fpage>1683</fpage>–<lpage>1688</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711413893">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svensson</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Abrahamsson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dellborg</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events</article-title>. <source>Eur Heart J</source>. <year>2005</year>;<volume>26</volume>(<issue>13</issue>):<fpage>1255</fpage>–<lpage>1261</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711413893">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosiborod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>301</volume>(<issue>15</issue>):<fpage>1556</fpage>–<lpage>1564</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711413893">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Díaz</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>(<issue>24</issue>):<fpage>2429</fpage>–<lpage>2437</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711413893">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mellbin</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Malmberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Waldenström</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wedel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rydén</surname>
<given-names>L</given-names>
</name>
</person-group>
<collab collab-type="author">DIGAMI 2 investigators</collab>. <article-title>Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial</article-title>. <source>Heart</source>. <year>2009</year>;<volume>95</volume>(<issue>9</issue>):<fpage>721</fpage>–<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711413893">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliver</surname>
<given-names>MF</given-names>
</name>
</person-group>. <article-title>Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes</article-title>. <source>Am J Med</source>. <year>2002</year>;<volume>112</volume>(<issue>4</issue>):<fpage>305</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr27-0003319711413893">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scognamiglio</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Negut</surname>
<given-names>C</given-names>
</name>
<name>
<surname>De Kreutzenberg</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Tiengo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Avogaro</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>112</volume>(<issue>2</issue>):<fpage>179</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711413893">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gresele</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Guglielmini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>De Angelis</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>41</volume>(<issue>6</issue>):<fpage>1013</fpage>–<lpage>1020</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711413893">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aljada</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ghanim</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Glucose ingestion induces an increase in intranuclear nuclear factor kappa B, a fall in cellular inhibitor kappa B, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects</article-title>. <source>Metabolism</source>. <year>2006</year>;<volume>55</volume>(<issue>9</issue>):<fpage>1177</fpage>–<lpage>1185</lpage>.</citation>
</ref>
<ref id="bibr30-0003319711413893">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Motoyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirashima</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery</article-title>. <source>J Am Coll Cardiol</source>. <year>1999</year>;<volume>34</volume>(<issue>1</issue>):<fpage>146</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr31-0003319711413893">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohanty</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hamouda</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Aljada</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ghanim</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dandona</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2000</year>;<volume>85</volume>(<issue>8</issue>):<fpage>2970</fpage>–<lpage>2973</lpage>.</citation>
</ref>
<ref id="bibr32-0003319711413893">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galassetti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>SN</given-names>
</name>
</person-group>. <article-title>Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia</article-title>. <source>Clin Sci (Lond)</source>. <year>2000</year>;<volume>99</volume>(<issue>5</issue>):<fpage>351</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr33-0003319711413893">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heller</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome?</article-title> <source>Int J Clin Pract Suppl</source>. <year>2002</year>;<volume>129</volume>:<fpage>27</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr34-0003319711413893">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malmberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rydén</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wedel</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity</article-title>. <source>Eur Heart J</source>. <year>2005</year>;<volume>26</volume>(<issue>7</issue>):<fpage>650</fpage>–<lpage>661</lpage>.</citation>
</ref>
<ref id="bibr35-0003319711413893">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>McLean</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The Hyperglycemia: intensive insulin infusion in infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction</article-title>. <source>Diabetes Care</source>. <year>2006</year>;<volume>29</volume>(<issue>4</issue>):<fpage>765</fpage>–<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr36-0003319711413893">
<label>36</label>
<citation citation-type="journal">
<collab collab-type="author">The BARI 2D Study Group</collab>. <article-title>A randomized trial of therapies for type 2 diabetes and coronary artery disease</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>24</issue>):<fpage>2503</fpage>–<lpage>2515</lpage>.</citation>
</ref>
<ref id="bibr37-0003319711413893">
<label>37</label>
<citation citation-type="journal">
<collab collab-type="author">The ADVANCE Collaborative Group</collab>. <article-title>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>(<issue>24</issue>):<fpage>2560</fpage>–<lpage>2572</lpage>.</citation>
</ref>
<ref id="bibr38-0003319711413893">
<label>38</label>
<citation citation-type="journal">
<collab collab-type="author">The Action to Control Cardiovascular Risk in Diabetes Study Group</collab>. <article-title>Effects of intensive glucose lowering in type 2 diabetes</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>(<issue>24</issue>):<fpage>2545</fpage>–<lpage>2559</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>